Erin Morgan

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Rohit Loomba, Erin Morgan, Lynnetta M. Watts et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 114 citations

Metabolic Syndrome, Placebo-controlled Phase 2, Hepatology +13

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx

Erin Morgan, Yvonne Tami, Kuolung Hu et al. · JACC Basic to Translational Science · 2021 · 84 citations · Full text

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

Erin Morgan, Nguyen C. Pham, Julia K. Overman et al. · Diabetes Care · 2019 · 49 citations

First proof of pharmacology in humans of a novel glucagon receptor antisense drug

Marloes G. J. van Dongen, Bart F. Geerts, Erin Morgan et al. · The Journal of Clinical Pharmacology · 2014 · 43 citations

First Proof, Pharmacotherapy, Experimental Pharmacology +16

Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes

Andrés Digenio, Nguyen C. Pham, Lynnetta M. Watts et al. · Diabetes Care · 2018 · 41 citations